Frankfurt
22.01.25
08:11 Uhr
0,181 Euro
+0,008
+4,49 %
+4,49 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 112 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
| 17.09.24 | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 327 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen | |
| 21.08.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2024 | 176 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 21, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2024 is now available, in Swedish, on the... ► Artikel lesen | |
| 30.07.24 | Isofol Medical AB: Isofol appoints Magdalena Hagman as new Chief Financial Officer | 218 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 30, 2024 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive... ► Artikel lesen | |
| 16.07.24 | Isofol Medical AB: Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin | 314 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies that support the dose-response relationship for arfolitixorin.... ► Artikel lesen | |
| 08.05.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-March 2024 | 422 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 8, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-March 2024 is now available, in Swedish, on the... ► Artikel lesen | |
| 20.02.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2023 | 234 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 20, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2023 is now available on the company's... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,015 | -29,63 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| VALNEVA | 2,212 | -1,51 % | Valneva: Hohe Immunantwort durch Chikungunya-Impfstoff | Valneva hat neue Phase-3-Daten für den Chikungunya-Impfstoff IXCHIQ veröffentlicht, die eine anhaltend hohe Immunantwort bei Jugendlichen bestätigen. Ein Jahr nach der einmaligen Impfung zeigten Studienteilnehmer... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,040 | 0,00 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,898 | +3,71 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,790 | +9,99 % | Here's Why You Should Retain PacBio Stock in Your Portfolio for Now | ||
| CARDIOL THERAPEUTICS | 1,226 | +5,51 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| CENTOGENE | 0,100 | 0,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,485 | +3,45 % | Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role | ||
| BIOMERIEUX | 112,70 | -0,27 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| CYCLACEL | 0,338 | -3,15 % | Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs | BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,195 | -2,01 % | Kia India Begins Production of Syros SUV | Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024New family-focused SUV specifically designed for customers in IndiaGroundbreaking... ► Artikel lesen | |
| GENUS | 20,800 | 0,00 % | Genus Sees H1 Adj. Profit Before Tax Ahead Of Expectations | LONDON (dpa-AFX) - Genus Plc (GNS.L), a biotechnology firm focused on animal genetics, said on Wednesday that it has recorded a strong performance for the first half and expects its earnings... ► Artikel lesen | |
| ANAPTYSBIO | 16,400 | +1,23 % | XFRA AN6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,181 Euro und damit +4,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.
